A Phase 1, First in Human, Dose-Escalation Study of UCT-01-097 in Participants With Advanced Solid Tumors
Latest Information Update: 18 Mar 2024
At a glance
- Drugs UCT-01-097 (Primary) ; Gemcitabine; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors 1200 Pharma
- 11 Mar 2024 Status changed from recruiting to discontinued. ( Stopped for strategic business reasons. The decision to stop the study was not connected to anysafety concerns, or new risk associated with the study product, intervention, or procedures.)
- 29 Mar 2021 Status changed from not yet recruiting to recruiting.
- 25 Feb 2021 New trial record